Eli Lilly & Co. (LLY)
1,129.35
-3.65 (0.32%)
Upcoming Events
Latest Headlines
Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
June 15, 2026 4:08 PM - StreetInsider
BMO Capital on Eli Lilly (LLY): 'Early Data for AJ1-11095 Impress at EHA'
June 15, 2026 10:11 AM - StreetInsider
Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
June 14, 2026 8:05 AM - StreetInsider
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026 3:15 AM - PR NewsWire
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
Form 4 ELI LILLY & Co For: Jun 10 Filed by: Yuffa Ilya
June 11, 2026 4:23 PM - SEC Filing
Form 144 ELI LILLY & Co Filed by: Yuffa Ilya
June 10, 2026 11:04 AM - SEC Filing
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026 9:30 AM - PR NewsWire
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
June 10, 2026 6:05 AM - StreetInsider
FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis
June 9, 2026 6:19 PM - StreetInsider
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026 6:19 PM - PR NewsWire
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
June 9, 2026 2:31 PM - StreetInsider
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
June 9, 2026 4:00 AM - BizWire
Lilly's oral diabetes drug outperforms rival in late-stage trials
June 8, 2026 2:31 PM - StreetInsider
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 8, 2026 2:30 PM - PR NewsWire
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
June 8, 2026 9:40 AM - StreetInsider
Truist on Eli Lilly (LLY): 'We see near-term and longer-term areas for growth'
June 8, 2026 9:21 AM - StreetInsider
Lilly reports weight loss data for Foundayo across menopause stages
June 8, 2026 2:56 AM - StreetInsider
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 7, 2026 11:00 AM - PR NewsWire
Pfizer targets obesity market with monthly weight-loss injection data
June 6, 2026 6:03 PM - StreetInsider
Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide
June 6, 2026 6:03 PM - StreetInsider
Eli Lilly reports positive results for obesity drug retatrutide trials
June 6, 2026 2:53 PM - StreetInsider
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
June 6, 2026 2:30 PM - PR NewsWire
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM - StreetInsider
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
June 5, 2026 7:05 AM - StreetInsider
ADA 2026 preview: All eyes on these 2 stocks
June 4, 2026 7:00 PM - StreetInsider
Weight Watchers integrates with Eli Lilly's LillyDirect platform
June 4, 2026 8:03 AM - StreetInsider
Lilly cuts Germany investment plan in half over healthcare reforms
June 3, 2026 1:17 PM - StreetInsider
Lilly to present hematology data at European meeting in Stockholm
June 2, 2026 9:30 AM - StreetInsider
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026 9:30 AM - PR NewsWire
Form 25-NSE ELI LILLY & Co Filed by: NEW YORK STOCK EXCHANGE LLC
June 2, 2026 9:17 AM - SEC Filing
Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
June 1, 2026 11:35 AM - StreetInsider
Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
June 1, 2026 9:05 AM - StreetInsider
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
June 1, 2026 2:53 AM - StreetInsider
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide
May 31, 2026 11:21 PM - StreetInsider
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026 8:01 AM - PR NewsWire
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 28, 2026 3:02 PM - SEC Filing
Lilly to present diabetes, obesity drug data at ADA conference
May 28, 2026 1:00 PM - StreetInsider
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026 1:00 PM - PR NewsWire
CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal
May 28, 2026 6:47 AM - StreetInsider
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026 6:45 AM - PR NewsWire
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026 11:15 AM - PR NewsWire
Lilly acquires three infectious disease companies for up to $3.83 billion
May 26, 2026 6:45 AM - StreetInsider
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026 6:45 AM - PR NewsWire
Eli Lilly & Co. (LLY) to buy three vaccine firms for up to $4B - WSJ
May 26, 2026 6:39 AM - StreetInsider
Lilly's VERVE-102 reduces cholesterol by up to 62% in phase 1b trial
May 26, 2026 5:50 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,251 at BofA Securities
May 26, 2026 5:26 AM - StreetInsider
Leerink Reiterates Outperform Rating on Eli Lilly (LLY)
May 26, 2026 3:05 AM - StreetInsider
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026 8:45 AM - PR NewsWire
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 22, 2026 2:05 PM - SEC Filing
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
May 22, 2026 9:24 AM - StreetInsider
Eli Lilly reports weight loss data for obesity drug in older adults
May 22, 2026 8:50 AM - StreetInsider
Lilly to present oncology data at ASCO 2026 meeting
May 21, 2026 5:02 PM - StreetInsider
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 5:00 PM - PR NewsWire
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
May 21, 2026 9:00 AM - StreetInsider
Lilly's retatrutide shows significant weight loss in phase 3 trial
May 21, 2026 6:45 AM - StreetInsider
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026 6:45 AM - PR NewsWire
Form 8-K ELI LILLY & Co For: May 20
May 20, 2026 4:31 PM - SEC Filing
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 20, 2026 4:22 PM - SEC Filing
Eli Lilly & Co. (LLY) Acquires Engage Biologics for Up to $202M in Cash
May 20, 2026 9:37 AM - StreetInsider
Form 4 ELI LILLY & Co For: May 18 Filed by: Sulzberger Gabrielle
May 19, 2026 4:20 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: LUCIANO JUAN R
May 19, 2026 4:19 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: Fyrwald J Erik
May 19, 2026 4:18 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 18 Filed by: Alvarez Ralph
May 19, 2026 4:16 PM - SEC Filing
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
May 18, 2026 10:00 AM - PR NewsWire
Eli Lilly loses Supreme Court appeal of $194 million fraud award
May 18, 2026 9:57 AM - StreetInsider
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
May 16, 2026 11:00 AM - PR NewsWire
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026 7:00 AM - PR NewsWire
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
May 13, 2026 9:24 AM - StreetInsider
Eli Lilly launches Alzheimer's drug in India at $957 per vial
May 13, 2026 5:57 AM - StreetInsider
Lilly reports weight maintenance with Foundayo and reduced-dose Zepbound
May 12, 2026 6:01 PM - StreetInsider
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 12, 2026 6:01 PM - PR NewsWire
FDA Commissioner Marty Makary to step down - Politico
May 12, 2026 12:52 PM - StreetInsider
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
May 12, 2026 12:00 PM - PR NewsWire
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
May 12, 2026 9:00 AM - StreetInsider
Form SD ELI LILLY & Co
May 11, 2026 4:31 PM - SEC Filing
The Next Generation of the GLP-1 Revolution Is Already Underway
May 11, 2026 8:30 AM - Globe NewsWire
Health officials explore restrictions on certain SSRI antidepressants - Reuters
May 8, 2026 12:04 PM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,235 at Guggenheim
May 8, 2026 7:22 AM - StreetInsider
Form 424B2 ELI LILLY & Co
May 8, 2026 6:09 AM - SEC Filing
Form 8-K ELI LILLY & Co For: May 04
May 7, 2026 4:42 PM - SEC Filing
Form 4 ELI LILLY & Co For: May 06 Filed by: LILLY ENDOWMENT INC
May 7, 2026 4:00 PM - SEC Filing
Biotech’s Next Wave May Already be in Motion
May 7, 2026 8:45 AM - Globe NewsWire
Form FWP ELI LILLY & Co Filed by: ELI LILLY & Co
May 6, 2026 5:25 PM - SEC Filing
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
May 6, 2026 4:36 PM - SEC Filing
Eli Lilly invests additional $4.5 billion in Indiana manufacturing sites
May 6, 2026 9:01 AM - StreetInsider
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 6, 2026 9:00 AM - PR NewsWire
Form 424B2 ELI LILLY & Co
May 6, 2026 8:05 AM - SEC Filing
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
May 5, 2026 12:30 PM - StreetInsider
Lilly's Omvoh shows sustained disease remission in ulcerative colitis study
May 5, 2026 6:48 AM - StreetInsider
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026 6:45 AM - PR NewsWire
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
May 4, 2026 11:14 AM - StreetInsider
Lilly declares second-quarter 2026 dividend
May 4, 2026 11:11 AM - PR NewsWire
RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'
May 4, 2026 10:26 AM - StreetInsider
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
May 4, 2026 9:27 AM - StreetInsider
Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
May 4, 2026 9:20 AM - StreetInsider
Bernstein: We're buyers of weakness in LLY
May 4, 2026 9:15 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
May 4, 2026 8:58 AM - StreetInsider
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
May 4, 2026 8:57 AM - StreetInsider
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
May 4, 2026 8:44 AM - StreetInsider
Form SCHEDULE 13G ELI LILLY & Co Filed by: VANGUARD CAPITAL MANAGEMENT LLC
May 1, 2026 11:53 AM - SEC Filing
Eli Lilly (LLY) PT Lowered to $1,133 at BofA Securities
May 1, 2026 10:53 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,344 at Morgan Stanley
May 1, 2026 9:13 AM - StreetInsider
Novo Nordisk rebrands diabetes tablet as Ozempic in US
May 1, 2026 8:34 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,230 at Cantor Fitzgerald
May 1, 2026 7:13 AM - StreetInsider
Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third week
May 1, 2026 7:03 AM - StreetInsider
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
April 30, 2026 4:19 PM - StreetInsider
Form 10-Q ELI LILLY & Co For: Mar 31
April 30, 2026 11:26 AM - SEC Filing
FDA proposes to exclude semaglutide, tirzepatide from compounding list
April 30, 2026 9:23 AM - StreetInsider
Lilly surges on earnings beat and raised guidance
April 30, 2026 7:21 AM - StreetInsider
Form 8-K ELI LILLY & Co For: Apr 30
April 30, 2026 7:03 AM - SEC Filing
Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance
April 30, 2026 6:48 AM - StreetInsider
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
April 30, 2026 6:45 AM - PR NewsWire
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
April 30, 2026 3:28 AM - StreetInsider
Eli Lilly Q1 earnings preview: analysts eye outlook for obesity drugs
April 30, 2026 2:00 AM - StreetInsider
Form PX14A6G ELI LILLY & Co Filed by: Friends Fiduciary Corp
April 29, 2026 1:19 PM - SEC Filing
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
April 29, 2026 11:15 AM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 1.5 calls to 1 put into quarter results
April 29, 2026 4:39 AM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put into quarter results
April 28, 2026 11:30 AM - StreetInsider
Lilly to acquire Ajax Therapeutics for up to $2.3 billion
April 27, 2026 6:45 AM - StreetInsider
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
April 27, 2026 6:45 AM - PR NewsWire
Eli Lilly (LLY) PT Lowered to $$1,058 at Leerink Partners
April 27, 2026 6:21 AM - StreetInsider
AI is starting to impact the pharma sector — These 2 stocks are seen as NT winners
April 25, 2026 4:00 AM - StreetInsider
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
April 24, 2026 7:27 AM - StreetInsider
Eli Lilly & Co. (LLY) shares trade lower on weak Foundayo launch
April 24, 2026 6:28 AM - StreetInsider
Hims & Hers expands platform to include Eli Lilly weight loss medications
April 23, 2026 8:40 AM - StreetInsider
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
April 23, 2026 6:19 AM - StreetInsider
Bernstein: Potential for Beat to Drive Eli Lilly (LLY) Stock
April 22, 2026 8:38 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,183 at Guggenheim
April 22, 2026 7:15 AM - StreetInsider
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
April 21, 2026 4:22 PM - StreetInsider
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Sulzberger Gabrielle
April 21, 2026 4:21 PM - SEC Filing
Form 4 ELI LILLY & Co For: Apr 20 Filed by: LUCIANO JUAN R
April 21, 2026 4:19 PM - SEC Filing
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Fyrwald J Erik
April 21, 2026 4:17 PM - SEC Filing
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Alvarez Ralph
April 21, 2026 4:15 PM - SEC Filing
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
April 21, 2026 1:33 PM - StreetInsider
Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
April 21, 2026 11:03 AM - StreetInsider
CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
April 21, 2026 10:53 AM - StreetInsider
UBS Reiterates Buy Rating on Eli Lilly (LLY)
April 21, 2026 9:41 AM - StreetInsider
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
April 21, 2026 7:19 AM - StreetInsider
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
April 20, 2026 3:26 PM - SEC Filing
RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justified
April 20, 2026 11:20 AM - StreetInsider
RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'
April 20, 2026 10:51 AM - StreetInsider
Lilly to acquire Kelonia Therapeutics for up to $7 billion
April 20, 2026 9:01 AM - StreetInsider
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
April 20, 2026 9:00 AM - PR NewsWire
Eli Lilly & Co. (LLY) nears deal to acquire Kelonia Therapeutics - WSJ
April 19, 2026 5:26 PM - StreetInsider
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
April 17, 2026 9:57 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
April 17, 2026 8:14 AM - StreetInsider
Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
April 16, 2026 10:52 AM - StreetInsider
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
April 16, 2026 10:01 AM - PR NewsWire
Walmart expands weight management services with virtual care platform
April 16, 2026 8:40 AM - StreetInsider
Eli Lilly's Foundayo meets cardiovascular safety goal in diabetes study
April 16, 2026 6:45 AM - StreetInsider
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of card
April 16, 2026 6:45 AM - PR NewsWire
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
April 15, 2026 9:39 AM - StreetInsider
Eli Lilly to acquire CrossBridge Bio for up to $300 million
April 14, 2026 8:07 AM - StreetInsider
Leerink stays Outperform on Eli Lilly (LLY) after Jaypirca Ph3 results
April 13, 2026 3:02 PM - StreetInsider
Lilly's Jaypirca shows positive results in blood cancer trial
April 13, 2026 6:45 AM - StreetInsider
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
April 13, 2026 6:45 AM - PR NewsWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 2 calls to 1 put as share price down 1.7%
April 10, 2026 11:01 AM - StreetInsider
RBC Capital 'Expecting GLP-1 Sales Strength' for Eli Lilly (LLY)
April 10, 2026 8:35 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,327 at Morgan Stanley
April 10, 2026 8:15 AM - StreetInsider
Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery
April 9, 2026 7:39 AM - StreetInsider
GoodRx offers Eli Lilly's new oral GLP-1 drug at $149 monthly
April 9, 2026 7:30 AM - StreetInsider
Lilly launches Foundayo oral GLP-1 weight loss pill in US market
April 9, 2026 6:45 AM - StreetInsider
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026 6:45 AM - PR NewsWire
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald Ahead of Foundayo Launch
April 8, 2026 7:55 AM - StreetInsider
AC Immune amends Lilly collaboration for tau drug development
April 7, 2026 7:01 AM - StreetInsider
Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
April 2, 2026 8:47 AM - StreetInsider
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
April 2, 2026 7:28 AM - StreetInsider
Eli Lilly (LLY) PT Raised to $1,294 at BofA Securities
April 1, 2026 4:11 PM - StreetInsider
Leerink Partners reiterates Outperform on Eli Lilly (LLY) following orforglipron approval
April 1, 2026 3:08 PM - StreetInsider
Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO tells CNBC
April 1, 2026 1:45 PM - StreetInsider
Truist Securities Reiterates Eli Lilly (LLY) at Buy on Foundayo approval, 'remain bullish on Lilly'
April 1, 2026 12:53 PM - StreetInsider
FDA approves Lilly's oral weight loss drug Foundayo
April 1, 2026 11:33 AM - StreetInsider
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026 11:32 AM - PR NewsWire
FDA approves Foundayo weight loss pill in record 50 days
April 1, 2026 11:29 AM - StreetInsider
Barclays on Eli Lilly (LLY): Centessa a 'sensible tuck-in' for neuroscience division
March 31, 2026 12:30 PM - StreetInsider
Eli Lilly & Co. (LLY) call put ratio 2.8 calls to 1 put after acquiring Centessa (CNTA)
March 31, 2026 10:05 AM - StreetInsider
BMO Capital on Eli Lilly (LLY): Centessa deal positive for shares; 'diversifying business ahead of any major LOEs'
March 31, 2026 9:40 AM - StreetInsider
Centessa shares surge after Lilly unveils $6.3 billion takeover deal
March 31, 2026 7:23 AM - StreetInsider
Lilly to acquire Centessa for $6.3 billion to expand sleep disorder treatments
March 31, 2026 6:45 AM - StreetInsider
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
March 31, 2026 6:45 AM - PR NewsWire
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
March 31, 2026 6:35 AM - StreetInsider
Lilly partners with Insilico Medicine in AI drug discovery deal
March 30, 2026 8:22 AM - StreetInsider
Eli Lilly (LLY) PT Lowered to $1,163 at Guggenheim
March 30, 2026 7:10 AM - StreetInsider
Should you buy the dip in Novo Nordisk stock? Wall Street analyst answers
March 29, 2026 10:00 AM - StreetInsider
Lilly drug combo shows superior results in psoriatic arthritis study
March 28, 2026 3:15 PM - StreetInsider
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
March 28, 2026 3:15 PM - PR NewsWire
Lilly presents four-year data for EBGLYSS in atopic dermatitis study
March 27, 2026 9:01 AM - StreetInsider
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
March 27, 2026 9:00 AM - PR NewsWire
Morgan Stanley on Eli Lilly (LLY) following scripts: 'We see ~6% upside to '26 M+Z ests'
March 27, 2026 8:32 AM - StreetInsider
Jefferies on Eli Lilly (LLY) competition: Oral Wegovy's TRx came in at ~94.7k on IMS & ~80.1k on Symphony
March 27, 2026 8:16 AM - StreetInsider
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: VANGUARD GROUP INC
March 26, 2026 6:03 PM - SEC Filing
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put
March 25, 2026 6:16 AM - StreetInsider
Lilly gets FTC clearance for Innovent Biologics acquisition
March 24, 2026 9:45 AM - StreetInsider
Takeda, Lilly rejected by Supreme Court on Actos fraud lawsuit
March 23, 2026 9:34 AM - StreetInsider
Form DEFA14A ELI LILLY & Co
March 20, 2026 4:23 PM - SEC Filing
Form DEF 14A ELI LILLY & Co For: Mar 20
March 20, 2026 4:20 PM - SEC Filing
Jefferies: Oral Wegovy Outpacing Injectables; Lilly (LLY) Well-Positioned Ahead of April PDUFA
March 20, 2026 8:14 AM - StreetInsider
India's Eris Lifesciences launches generic semaglutide at $13.8 per month
March 20, 2026 7:31 AM - StreetInsider
Leerink Partners on Eli Lilly (LLY) following Retatrutide data
March 19, 2026 2:52 PM - StreetInsider
BMO on Eli Lilly (LLY): 'Triple Agonist Turns Double Play - Extending Positive Results to Both T2D and OA'
March 19, 2026 10:17 AM - StreetInsider
Morgan Stanley on Eli Lilly (LLY): retatrutide weight loss data 'encouraging,' but offset by GI adverse events
March 19, 2026 10:14 AM - StreetInsider
Truist Securities on Eli Lilly (LLY): retatrutide ph3 results 'favorable' but similar data to Mounjaro
March 19, 2026 9:08 AM - StreetInsider
Wolfe Research on Eli Lilly (LLY): ph3 retratrutide results point to potential 'best-in-class' weight loss
March 19, 2026 8:31 AM - StreetInsider
Lilly's retatrutide shows blood sugar, weight reduction in diabetes trial
March 19, 2026 6:45 AM - StreetInsider
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
March 19, 2026 6:45 AM - PR NewsWire
UBS Reiterates Buy Rating on Eli Lilly (LLY) Following Strong Q4, Upside Guidance
March 18, 2026 9:11 AM - StreetInsider
Form 4 ELI LILLY & Co For: Mar 16 Filed by: Sulzberger Gabrielle
March 17, 2026 4:36 PM - SEC Filing
Form 4 ELI LILLY & Co For: Mar 16 Filed by: LUCIANO JUAN R
March 17, 2026 4:34 PM - SEC Filing
Form 4 ELI LILLY & Co For: Mar 16 Filed by: Fyrwald J Erik
March 17, 2026 4:33 PM - SEC Filing
Form 4 ELI LILLY & Co For: Mar 16 Filed by: Alvarez Ralph
March 17, 2026 4:30 PM - SEC Filing
HSBC downgrades Eli Lilly, says shares are 'priced to perfection'
March 17, 2026 9:51 AM - StreetInsider
HSBC Downgrades Eli Lilly (LLY) to Reduce
March 17, 2026 3:33 AM - StreetInsider
Full Article List
